Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has issued an announcement.
Shanghai Fosun Pharmaceutical’s subsidiary, Jinzhou Avanc Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for its Metaraminol Bitartrate Injection. This development marks a significant step in the company’s product portfolio, potentially boosting its market position and offering new opportunities for growth in the pharmaceutical sector.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. operates in the pharmaceutical industry, focusing on the development, manufacturing, and sales of pharmaceutical products. The company is based in China and is involved in various healthcare-related sectors.
YTD Price Performance: -8.22%
Average Trading Volume: 1,184
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $7.73B
For an in-depth examination of 2196 stock, go to TipRanks’ Stock Analysis page.
